Damora TherapeuticsDMRA
13F holders, Q2 2025 (June 30)9holders −2
0new positions
2sold out
1famous investor
$3.40avg. 13F price*
At the end of Q2 2025, 9 institutions reported holding Damora Therapeutics Inc. (DMRA) in their 13F filings, down 2 from Q1 2025. 0 opened new positions and 2 sold out. The largest holders were Novo Holdings A/S ($341K), Renaissance Technologies ($50K) and Susquehanna International Group, LLP ($45K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Damora Therapeutics Inc.
- Filed as
- GALECTO INC (Q2 2025)
- CUSIP
- 36322Q206
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 2 | $40K |
All 13F filers, Q1 2025 → Q2 2025: 4,910 shares bought and 14,851 shares sold, net −9,941 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Novo Holdings A/S | 0.02% | No change | 99,913 | $341K |
| Renaissance Technologies | 0.00% | Reduce -5.2% | 14,544 | $50K |
| Susquehanna International Group, LLP | 0.00% | Add +26.9% | 13,602 | $45K |
| UBS Group AG | 0.00% | Add +711.6% | 2,313 | $8K |
| Bank of America Corp. | 0.00% | Add +0.2% | 1,228 | $4K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -40.5% | 942 | $3K |
| Barclays PLC | 0.00% | Reduce -24.8% | 100 | $341 |
| BlackRock, Inc. | 0.00% | Reduce -79.6% | 100 | $341 |
| SBI Securities Co., Ltd. | 0.00% | No change | 18 | $61 |
"% of holder's portfolio" is DMRA's weight in each manager's 13F, not the share of Damora Therapeutics Inc. the manager owns.